Shree Ganesh Remedies Limited
BSE: SGRL · Pharmaceuticals
Snapshot
Unlock Shree Ganesh Remedies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shree Ganesh Remedies Ltd. is a pharmaceutical company focused on the research, development, and manufacturing of healthcare products. Its portfolio encompasses pharmaceutical intermediates, veterinary products, and bulk drugs.
Business Model
The company operates as a manufacturer and marketer of chemical and pharmaceutical products, leveraging its research capabilities to serve both human and veterinary healthcare markets.
Growth Outlook
Growth is driven by the expansion of its product portfolio in the pharmaceutical and veterinary sectors and the continuous development of new chemical intermediates.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where non-compliance could lead to operational disruptions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and raw materials can significantly impact profit margins.
- Environmental Regulations. As a chemical manufacturer, the company faces risks related to evolving environmental laws and waste management requirements in India.
- Market Competition. The pharmaceutical intermediate sector is highly competitive, posing risks to pricing power and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Shree Ganesh Remedies Limited and 5,000+ companies — free.
Key Metrics
P/E
51.2x
Q4 FY26 · consolidated
EV/EBITDA
24.3x
Q4 FY26 · consolidated
NET PROFIT MARGIN
18.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Shree Ganesh Remedies LimitedSGRL | ₹909 Cr | 51.23 | 24.35 | — | 34.8% | 11.9% | 15.9% | +19.9% |
Bharat Parenterals LimitedBPLPHARMA | ₹1,057 Cr | 37.27 | 16.39 | 9.4% | 21.2% | 8.3% | 9.0% | +10.9% |
WanburyWANBURY | ₹860 Cr | 14.18 | 10.79 | 3.6% | 15.2% | 54.9% | 29.2% | -11.3% |
Anlon HealthcareAHCL | ₹833 Cr | 2.81 | 18.34 | — | 27.4% | 13.9% | 21.3% | -82.8% |
Anuh PharmaANUHPHR | ₹813 Cr | 22.65 | 11.21 | 9.7% | 9.2% | 13.0% | 17.7% | -5.1% |
Amanta HealthcarAMANTA | ₹753 Cr | 46.64 | 14.50 | — | 21.5% | 6.7% | 9.9% | — |
As of Q4 FY26
Financials
Shree Ganesh Remedies Limited
BSE: SGRL · Pharmaceuticals
Snapshot
Unlock Shree Ganesh Remedies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shree Ganesh Remedies Ltd. is a pharmaceutical company focused on the research, development, and manufacturing of healthcare products. Its portfolio encompasses pharmaceutical intermediates, veterinary products, and bulk drugs.
Business Model
The company operates as a manufacturer and marketer of chemical and pharmaceutical products, leveraging its research capabilities to serve both human and veterinary healthcare markets.
Growth Outlook
Growth is driven by the expansion of its product portfolio in the pharmaceutical and veterinary sectors and the continuous development of new chemical intermediates.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where non-compliance could lead to operational disruptions.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs and raw materials can significantly impact profit margins.
- Environmental Regulations. As a chemical manufacturer, the company faces risks related to evolving environmental laws and waste management requirements in India.
- Market Competition. The pharmaceutical intermediate sector is highly competitive, posing risks to pricing power and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Shree Ganesh Remedies Limited and 5,000+ companies — free.
Key Metrics
P/E
51.2x
Q4 FY26 · consolidated
EV/EBITDA
24.3x
Q4 FY26 · consolidated
NET PROFIT MARGIN
18.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26